---
title: "Yazdi Reiterates Buy on Sionna, Keeps $58 Price Target Ahead of High-Impact 2026 SION-719 Readout"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286238574.md"
description: "Kambiz Yazdi from BTIG has reiterated a Buy rating on Sionna Therapeutics, Inc. with a price target of $58.00, citing the company's advancing clinical pipeline and promising data for its lead asset, SION-719. The Phase 2a PreciSION CF trial has completed enrollment, and prior results indicate strong engagement and tolerability. Yazdi emphasizes the significance of reducing sweat chloride levels, with the 2026 readout expected to be a major catalyst. LifeSci Capital also maintains a Buy rating with a $60.00 target."
datetime: "2026-05-13T10:05:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286238574.md)
  - [en](https://longbridge.com/en/news/286238574.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286238574.md)
---

# Yazdi Reiterates Buy on Sionna, Keeps $58 Price Target Ahead of High-Impact 2026 SION-719 Readout

In a report released yesterday, Kambiz Yazdi from BTIG maintained a Buy rating on Sionna Therapeutics, Inc., with a price target of $58.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Kambiz Yazdi has given his Buy rating due to a combination of factors including Sionna’s advancing clinical pipeline and de‑risking data for its lead asset, SION-719. The company has completed enrollment in its Phase 2a PreciSION CF trial testing SION-719 on top of Trikafta in F508del homozygous cystic fibrosis patients, and prior preclinical and Phase 1 results suggest strong target engagement, meaningful CFTR restoration, and good tolerability at relatively low doses.

Yazdi also points to the clinical importance of further lowering sweat chloride, a validated biomarker where many Trikafta-treated patients still fall short of levels associated with near-normal CFTR function. Because SION-719 is designed to stabilize the NBD1 domain and aims for at least a 10 mmol/L sweat chloride reduction beyond Trikafta, he views the upcoming 2026 readout as a high-impact catalyst, and underpins his unchanged $58 price target with a valuation framework primarily based on a long-dated DCF complemented by a peak-sales multiple approach.

According to TipRanks, Yazdi is a 5-star analyst with an average return of 30.6% and a 73.81% success rate. Yazdi covers the Healthcare sector, focusing on stocks such as Zevra Therapeutics, Sionna Therapeutics, Inc., and Praxis Precision Medicines.

In another report released yesterday, LifeSci Capital also maintained a Buy rating on the stock with a $60.00 price target.

### Related Stocks

- [SION.US](https://longbridge.com/en/quote/SION.US.md)
- [ZVRA.US](https://longbridge.com/en/quote/ZVRA.US.md)
- [PRAX.US](https://longbridge.com/en/quote/PRAX.US.md)

## Related News & Research

- [Sionna Therapeutics (SION) Pulls Back On CF Hopes With Valuation Still In Focus](https://longbridge.com/en/news/293289887.md)
- [What Are Wall Street Analysts' Target Price for Kenvue Stock?](https://longbridge.com/en/news/294177426.md)
- [Sugar Prices Fall as Crude Oil Plunges](https://longbridge.com/en/news/294093253.md)
- [Analyst Reiterates Buy on Seanergy Maritime, Sees Upside from Stronger Earnings and Balance Sheet with Unchanged $20 Price Target](https://longbridge.com/en/news/293825646.md)
- [Sam Slutsky Maintains Buy Rating and $6 Price Target on ALLOHA-2 Progress and Cohort C Data De-Risking TSC-101 Program](https://longbridge.com/en/news/294251107.md)